Anti-neuropilin-1 peptide inhibition of synoviocyte survival, angiogenesis, and experimental arthritis.

OBJECTIVE To delineate the role of neuropilin-1 (NP-1), a vascular endothelial growth factor receptor (VEGFR), in rheumatoid inflammation and to determine whether blockade of NP-1 could suppress synoviocyte survival and angiogenesis. METHODS VEGF(111-165) peptide, which encompasses the NP-1 binding domain of VEGF(165), was generated by cleaving VEGF(165) with plasmin. The effect of this peptide on the interaction between VEGF(165) and its receptor was determined by (125)I-VEGFR binding assay. Assays to determine synoviocyte apoptosis, adhesion, and migration were performed in the presence of VEGF(165) and/or the peptide. VEGF(165)-induced angiogenesis was assessed by measuring the proliferation, tube formation, and wounding migration of endothelial cells (ECs). Mice were immunized with type II collagen to induce experimental arthritis. RESULTS VEGF(111-165) peptide specifically inhibited the binding of (125)I-VEGF(165) to NP-1 on rheumatoid synoviocytes and ECs. The peptide eliminated the VEGF(165)-mediated increase in synoviocyte survival and activation of p-ERK and Bcl-2. The peptide also completely inhibited a VEGF(165)-induced increase in synoviocyte adhesion and migration. In addition, the anti-NP-1 peptide blocked VEGF(165)-stimulated proliferation, capillary tube formation, and wounding migration of ECs in vitro. VEGF(165)-induced neovascularization in a Matrigel plug in mice was also blocked by treatment with the peptide. Finally, subcutaneous injection of anti-NP-1 peptide suppressed arthritis severity and autoantibody formation in mice with experimental arthritis and inhibited synoviocyte hyperplasia and angiogenesis in arthritic joints. CONCLUSION Anti-NP-1 peptide suppressed VEGF(165)-induced increases in synoviocyte survival and angiogenesis, and thereby blocked experimental arthritis. Our findings suggest that anti-NP-1 peptide could be useful in alleviating chronic arthritis.

[1]  S. Kambhampati,et al.  VEGF-A165 induces human aortic smooth muscle cell migration by activating neuropilin-1-VEGFR1-PI3K axis. , 2008, Biochemistry.

[2]  K. Kłosowska,et al.  Fractalkine is a novel chemoattractant for rheumatoid arthritis fibroblast-like synoviocyte signaling through MAP kinases and Akt. , 2007, Arthritis and rheumatism.

[3]  M. Reed,et al.  Neuropilins in physiological and pathological angiogenesis , 2007, The Journal of pathology.

[4]  M. Crépin,et al.  Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. , 2006, Life sciences.

[5]  Mi-Sook Lee,et al.  Interaction of Vascular Endothelial Growth Factor 165 with Neuropilin-1 Protects Rheumatoid Synoviocytes from Apoptotic Death by Regulating Bcl-2 Expression and Bax Translocation1 , 2006, The Journal of Immunology.

[6]  S. Ryu,et al.  Serum Amyloid A Binding to Formyl Peptide Receptor-Like 1 Induces Synovial Hyperplasia and Angiogenesis1 , 2006, The Journal of Immunology.

[7]  J. Park,et al.  Up-regulated transforming growth factor β–inducible gene h3 in rheumatoid arthritis mediates adhesion and migration of synoviocytes through αvβ3 integrin: Regulation by cytokines , 2006 .

[8]  K. Miyazawa,et al.  Calcineurin Is Expressed and Plays a Critical Role in Inflammatory Arthritis1 , 2006, The Journal of Immunology.

[9]  A. Bazarbachi,et al.  Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. , 2006, American journal of ophthalmology.

[10]  M. Brenner,et al.  Role of adhesion molecules in synovial inflammation , 2006, Current opinion in rheumatology.

[11]  落海 健彦.  Neuropilin-1 is involved in regulation of apoptosis and migration of human colon cancer , 2006 .

[12]  M. Klagsbrun,et al.  Soluble neuropilin targeted to the skin inhibits vascular permeability , 2005, Angiogenesis.

[13]  Chi-Bom Chae,et al.  Arginine-Rich Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Hexapeptide Inhibits Collagen-Induced Arthritis and VEGF-Stimulated Productions of TNF-α and IL-6 by Human Monocytes 1 , 2005, The Journal of Immunology.

[14]  Y. Gho,et al.  Specific interaction of VEGF165 with β‐amyloid, and its protective effect on β‐amyloid‐induced neurotoxicity , 2005 .

[15]  O. Fernandez-Capetillo,et al.  Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. , 2005, Blood.

[16]  K. Acharya,et al.  Identification of Placenta Growth Factor Determinants for Binding and Activation of Flt-1 Receptor* , 2004, Journal of Biological Chemistry.

[17]  I. Bernard-Pierrot,et al.  Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis , 2004, Oncogene.

[18]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[19]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[20]  P. Gaulard,et al.  A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response , 2003, Nature Immunology.

[21]  S. Soker,et al.  In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. , 2002, Blood.

[22]  K. Okawa,et al.  Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. , 2002, Human immunology.

[23]  A. Wunder,et al.  Synovial mast cells require C5a receptor (CD88) for arthritis induction , 2003, Arthritis Research & Therapy.

[24]  Nijole Gasiunas,et al.  Neuropilin-1 Binds Vascular Endothelial Growth Factor 165, Placenta Growth Factor-2, and Heparin via Its b1b2 Domain* , 2002, The Journal of Biological Chemistry.

[25]  M. Tessier-Lavigne,et al.  Neuropilins as Semaphorin Receptors , 2002 .

[26]  M. Tessier-Lavigne,et al.  Neuropilins as Semaphorin receptors: in vivo functions in neuronal cell migration and axon guidance. , 2002, Advances in experimental medicine and biology.

[27]  M. Lingen,et al.  Neuropilin-1 participates in wound angiogenesis. , 2002, The American journal of pathology.

[28]  P. Li,et al.  In Cardiomyocyte Hypoxia, Insulin-Like Growth Factor-I-Induced Antiapoptotic Signaling Requires Phosphatidylinositol-3-OH-Kinase-Dependent and Mitogen-Activated Protein Kinase-Dependent Activation of the Transcription Factor cAMP Response Element-Binding Protein , 2001, Circulation.

[29]  L. Shaw,et al.  Advances in Brief Vascular Endothelial Growth Factor Is an Autocrine Survival Factor for Neuropilin-expressing Breast Carcinoma Cells 1 , 2001 .

[30]  S. S. Lee,et al.  Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. , 2001, Clinical and experimental rheumatology.

[31]  K. Garcia,et al.  The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. , 2000, The Journal of biological chemistry.

[32]  K. Heidenreich,et al.  Akt/Protein Kinase B Up-regulates Bcl-2 Expression through cAMP-response Element-binding Protein* , 2000, The Journal of Biological Chemistry.

[33]  S. Soker,et al.  Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Goldring,et al.  Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. , 2000, Arthritis and rheumatism.

[35]  A. Koch,et al.  Angiogenesis: Implications for rheumatoid arthritis , 1998 .

[36]  Shay Soker,et al.  Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.

[37]  S. Soker,et al.  Inhibition of Vascular Endothelial Growth Factor (VEGF)-induced Endothelial Cell Proliferation by a Peptide Corresponding to the Exon 7-Encoded Domain of VEGF165 * , 1997, The Journal of Biological Chemistry.

[38]  D. Green,et al.  Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[39]  L. Pirilä,et al.  H-ras oncogene point mutations in arthritic synovium. , 1997, Arthritis and rheumatism.

[40]  M. Tessier-Lavigne,et al.  Neuropilin Is a Receptor for the Axonal Chemorepellent Semaphorin III , 1997, Cell.

[41]  G. Firestein.  Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? , 1996, Arthritis and rheumatism.

[42]  Hung V. Nguyen,et al.  The Carboxyl-terminal Domain(111165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency (*) , 1996, The Journal of Biological Chemistry.

[43]  B. Keyt,et al.  Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors , 1996, The Journal of Biological Chemistry.

[44]  M. Feldmann,et al.  Rheumatoid Arthritis , 1996, Cell.

[45]  C. Werning.  [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.